Background-Injection of bone marrow mononuclear cells has been reported to promote neovascularization of ischemic tissues effectively. We found that peripheral blood mononuclear cells were as efficient as bone marrow mononuclear cells for the treatment of limb ischemia in animals and showed that this treatment was feasible and safe in no-option patients with limb ischemia. However, the long-term outcome of such therapy has not been investigated. Methods and Results-We retrospectively analyzed the data for 42 patients who were treated between July 2002 and December 2005 by using the log-rank test, the Kaplan-Meier method, and the Cox proportional hazard model. Improvement of ischemic symptoms was observed in 60% to 70% of the patients. The annual rate of major amputation was decreased markedly by treatment. Improvement of ischemic symptoms was less marked in arteriosclerosis obliterans (ASO) patients on dialysis compared with nonhemodialysis ASO or thromboangiitis obliterans patients. Indeed, the survival rate of these patients was lower than that of nonhemodialysis ASO or thromboangiitis obliterans patients. Major adverse events such as death, major amputation, and cardiovascular events occurred mostly in ASO patients, and most of them were on dialysis. There was no significant difference in the cardiovascular event-free rate between responders and nonresponders. The survival rate of younger responders was better than that of nonresponders. Conclusions-Although this study was not placebo-controlled and these initial results were from a retrospective analysis, injection of peripheral blood mononuclear cells might be safe and potentially effective for the treatment of limb ischemia, but caution is needed when managing ASO patients on dialysis. 
P eripheral vascular disease (PVD) is mainly caused by atherosclerosis, and it results in obstruction of the blood supply to the lower or upper extremities. PVD is known to affect 10% to 15% of the adult population in developed countries and is often associated with coronary artery disease. 1 Arteriosclerosis obliterans (ASO) is the most common cause of PVD affecting the lower limbs. Peripheral ischemia can also arise from various types of vasculitis, including thromboangiitis obliterans (TAO) or Buerger's disease, which affects small-and medium-sized arteries and is related to tobacco use and male sex but not to other coronary risk factors. The 2 cardinal symptoms of limb ischemia are intermittent claudication and rest pain; the latter symptom occurs in patients with critical limb ischemia and often coincides with ischemic ulceration and/or gangrene. Treatment of PVD includes pharmacotherapy, percutaneous transluminal angioplasty, and vascular surgery, with the modality selected depending on the severity of symptoms and the arteries involved. 2 However, 30% to 50% of patients with critical limb ischemia require limb amputation within 1 year because of a poor response to treatment. 1, 2 
Clinical Perspective on p 254
Recent progress in understanding the mechanisms underlying vessel formation in adults as well as during embryogenesis has opened up a potential therapeutic avenue for patients without any current options. 3 In particular, the role of bone marrow-derived circulating endothelial progenitors has been studied extensively because these cells were identified in the peripheral blood, 4, 5 and it has been demonstrated that such cells contribute to both physiological and pathological angiogenesis in adults. 6, 7 These findings have led to the development of therapeutic neovascularization techniques using endothelial progenitor cells. Preclinical studies have indicated that injection of bone marrow mononuclear cells (BM-MNC), which contain endothelial progenitors, into ischemic limbs is very effective. 8 -10 Consequently, this therapeutic strategy has been tried for no-option patients with critical limb ischemia. The first clinical trial showed that injection of BM-MNC significantly improved tissue oxygenation and blood flow in ischemic limbs, resulting in a decrease of rest pain and the involution of ischemic ulcers. 11 More recent clinical studies have also demonstrated that intracoronary infusion of autologous BM-MNC in conjunction with standard treatment may improve left ventricular function after acute myocardial infarction. [12] [13] [14] [15] [16] However, these findings remain controversial because the studies were done on a relatively small scale and partially differed in design. A meta-analysis of 5 randomized controlled clinical trials [12] [13] [14] [15] [16] was published recently. 17 When the overall effect on the left ventricular ejection fraction at baseline and follow-up was assessed, there was significant improvement in the BM-MNC-treated group compared with the control group. Thus, transplantation of BM-MNC may be a safe and beneficial adjunctive treatment for acute myocardial infarction. Despite these promising results in the initial trials, the long-term outcome has not yet been reported.
We previously examined the possibility of therapeutic revascularization using peripheral blood mononuclear cells (PB-MNC) and found that injection of PB-MNC was as efficient as injection of BM-MNC for the treatment of limb ischemia in animal studies. 18 We then conducted a pilot trial of therapeutic revascularization using PB-MNC in no-option patients with critical limb ischemia and demonstrated that this treatment modality was both feasible and safe. 18, 19 In this study, we assessed the long-term outcome in patients receiving treatment with PB-MNC.
Methods

Patients and Study Design
We treated patients aged 20 to 80 years who had severe intermittent claudication, ischemic rest pain, or nonhealing ischemic ulcers caused by ASO or TAO, and who had not responded to conventional therapy that included nonsurgical and surgical revascularization. Before treatment, we performed a physical examination, laboratory tests, x-rays, electrocardiography, echocardiography, carotid ultrasonography, cardiac scintigraphy, and coronary angiography in all candidates. They also underwent arteriography of the lower extremities, measurement of ankle-brachial blood pressure index (ABPI), a laser Doppler study, and thermography to confirm the existence of PVD that was unsuitable for nonsurgical or surgical revascularization. We excluded patients with proliferative diabetic retinopathy and those with malignancy during the previous 5 years. We also excluded patients with limb ischemia resulting from causes other than ASO or TAO, such as collagen vascular diseases. We obtained written informed consent from all patients, and the ethics committee of Chiba University Graduate School of Medicine reviewed and approved the study protocol.
We retrospectively enrolled 42 patients who were treated between July 2002 and December 2005 and analyzed the data for them in December 2007. The data analyzed include the incidence of major amputation of treated limbs, improvement of rest pain, walking distance, ischemic ulcers (at least 25% reduction in size), and ABPI (an increase of more than 0.1). Rest pain was assessed as follows: ϩ4, severe pain that was not controlled by morphine, pentazocine, or nonsteroidal antiinflammatory drugs; ϩ3, moderate pain that required nonsteroidal antiinflammatory drugs; ϩ2, slight pain that did not need nonsteroidal antiinflammatory drugs; ϩ1, very slight pain; and 0, complete resolution. A responder was defined as a patient who showed at least 1 improvement of the following; rest pain, walking distance, ischemic ulcers, or ABPI at 6 months after treatment. A nonresponder was defined as a patient who showed no improvement of the above at 6 months after treatment. We performed follow-up examinations at 1, 6, 12, 24, and 36 months after treatment. We also monitored relapse of ischemic symptoms, adverse events, and the progression of atherosclerosis by the examinations described earlier. Estimation of ischemic myocardium was performed by singlephoton emission computed tomography (SPECT) imaging, as described previously. 20 
Injection of PB-MNC
PB-MNC were harvested by peripheral blood apheresis with a COBE Spectra Apheresis System (Gambro, Lakewood, Colo). Patient underwent apheresis for 240 minutes while awake and resting quietly. When the patient had severe anemia (hemoglobin Ͻ7.4 g/dL) or left ventricular dysfunction (ejection fraction Ͻ45%), the apheresis time was reduced to 180 minutes. The total leukocyte count and mononuclear cell count in the apheresis product was 1.5 to 2.0ϫ10 10 and 1 to 1.5ϫ10 10 , respectively. The product was concentrated to 20 mL by centrifugation at 2000g for 10 minutes and then was injected on the same day. PB-MNC were injected intramuscularly into the ischemic lower extremities at sites 1 to 3 cm apart, with each injection having a volume of 0.1 to 0.3 mL.
Statistical Analysis
All data were analyzed according to the intention-to-treat principle. For baseline variables, the groups were compared by using Fisher's Data are shown as meanϮSD (minimum-maximum; median) or n (%). CRF indicates chronic renal failure; HD, hemodialysis; CAD, coronary artery disease; CVD, cerebrovascular disease; VEGF, vascular endothelial growth factor. exact test or logistic regression for categorical outcomes and with t tests for continuous variables, as appropriate. For time-to-event outcomes, the lengths of time to a first event were compared by using the log-rank test, the Kaplan-Meier method was used to estimate the absolute risk of each event for each group, and hazard ratio and 95% confidence interval were estimated by the Cox proportional hazards model.
All comparisons were planned and tests were 2-sided, and a P value Ͻ0.05 was considered to indicate statistical significance. All statistical analyses were performed with the use of SAS software, version 9.1.3 (SAS Institute, Cary, NC).
Results
Patient Profile
After obtaining approval from the ethics committee of Chiba University Graduate School of Medicine, we conducted a pilot clinical trial in patients with critical limb ischemia caused by ASO or TAO for whom there were no conventional treatment options since July 2002. We found that therapeutic neovascularization by injection of PB-MNC was feasible and potentially effective for limb ischemia. Consequently, this therapy was approved as advanced medical care by the Japanese government in 2005, and we have treated about 70 patients with limb ischemia so far. Among them, we retrospectively analyzed the long-term outcome in 42 patients who were treated between July 2002 and December 2005. Most of these patients had been recommended to undergo major amputation before receiving PB-MNC because of chronic ischemic ulcers or gangrene resistant to conventional therapy, whereas some of them had severe intermittent claudication (Table 1 ). About half of the patients also suffered from chronic renal failure and were on hemodialysis 3 times weekly, whereas most of them had 1 or more complications (Table 1) .
Although the ASO patients were significantly older and had more risk factors for coronary artery disease than the TAO patients, the pretreatment ischemic status and rest pain did not differ between the 2 groups ( Table 2 ). More than 60% (18 of 28) of the ASO patients were on dialysis, whereas there were only 7.1% (1 of 14) on hemodialysis in the TAO group (Table 2) , and the hemodialysis group included more patients with ASO than the nonhemodialysis group (Table 3) . Before treatment, the severity of ischemia did not differ between the hemodialysis and nonhemodialysis groups (Table 3) . When the ASO patients were divided into groups with or without hemodialysis, there were no significant differences of the pretreatment ischemic status and rest pain or the number of risk factors (supplemental Table I ). Because the ASO and TAO populations might not have been comparable, we compared background factors among 3 groups, which were ASO patients on hemodialysis, nonhemodialysis ASO patients, and nonhemodialysis TAO patients. There were no differences in the pretreatment ischemic status and rest pain among the 3 groups, but the TAO patients had fewer coronary risk factors than the other groups (supplemental Table II ). 
Effect of Therapeutic Neovascularization With PB-MNC
Improvement of rest pain was observed in 72.2% (26 of 36) of the patients. The pain score decreased significantly and was nearly normalized by 12 months after treatment (PϽ0.05 versus before treatment in 1, 6, 12, 24 months, Figure 1A ). The maximum walking distance in 24 months after treatment also improved, although the increase was not significant (Pϭ0.07 versus before treatment in overall patients, Figure  1B ). Improvement of ischemic ulcers was observed in 66.7% (20 of 30) of the patients, and ulcer size showed a decrease after treatment in surviving patients without major amputation ( Figure 1C and 1F) . Among patients on hemodialysis, the improvement of rest pain and walking distance was less marked (Figure 1D and  1E) . Likewise, the improvement of ischemic status was smaller in ASO patients compared with TAO patients (Table  2) . Consequently, ASO patients on hemodialysis showed less improvement of ischemia than either nonhemodialysis ASO patients or TAO patients (supplemental Table II ). Four patients (9.5%) underwent major amputation within 1 year after treatment ( Figure 1G ), which was a much lower frequency than the reported annual amputation rate for patients with critical limb ischemia (30% to 50%). One TAO patient underwent major amputation during the observation period, whereas 5 major amputations were performed in ASO patients (4 of 5 were in ASO patients on dialysis; Figure 1G ).
Adverse Events After Therapeutic Revascularization With PB-MNC
Fifteen patients (35.7%) died of the causes unrelated to cell therapy, including cerebral infarction, sepsis, and chronic renal failure (Table 4) . In these patients, limb ischemia was caused by ASO, and most of them were on hemodialysis ( Table 4 ). The proportion of overall survival was 78.2% at 2 years and 63.9% at 3 years in our study population ( Figure   2A ). Additionally, the proportions of overall survival for patients on hemodialysis were significantly lower (57.9% at 2 years and 39.5% at 3 years) than those for nonhemodialysis patients, who had a survival rate of 84.4% at 3 years ( Figure  2A ). None of the TAO patients died during follow-up, whereas the overall survival proportion of ASO patients was 67.3% at 2 years and only 45.7% at 3 years (Figure 2A) . The survival rate of ASO patients on hemodialysis was lower than that of nonhemodialysis ASO patients or TAO patients (Figure 2A) .
Major adverse cardiovascular events (MACE) occurred in 13 out of 42 patients (31.0%; supplemental Table III) , and the proportion of MACE-free rate was 74.6% at 2 years and 71.5% at 3 years in our study population. The proportions of MACE-free rate were significantly lower in patients on hemodialysis (58.7% at 2 years and 51.3% at 3 years) than in nondialysis patients (86.5% at 3 years; Figure 2B ). MACE mostly occurred in ASO patients ( Figure 2B ), and most of them were on dialysis ( Figure 2B and supplemental Table III) .
Factors Associated With the Response to Treatment
We next investigated the factors that influenced the response to treatment. We divided the patients into responders (nϭ32) and nonresponders (nϭ10) according to a response score based on the improvement of rest pain, ischemic ulceration, walking distance, and ABPI. When we compared their background factors, there were no significant differences of the age, gender, Fontaine stage, coronary risk factors, and the number of CD34-positive cells between responders and nonresponders (Table 5) . Consistent with our previous findings, the peak plasma level of vascular endothelial growth factor after treatment was significantly higher in responders than in nonresponders (Table 5 ). Although the association was not significant, nonresponders included more ASO patients and had more complications such as dyslipidemia, hemodialysis, and coronary artery disease (Table 5 ). We also found that nonresponders tended to have more risk factors and lower vascular endothelial growth factor levels after treatment in the subgroups of ASO, TAO, dialysis, and nondialysis patients (supplemental Tables IV through VII) .
Relapse of rest pain occurred in 11.5% (3 of 26) of the patients whose rest pain was improved by treatment, and recurrence of ischemic ulcers was observed in 35.0% (7 of 20) of the patients whose ulcers had improved. Likewise, a decrease of ABPI and walking distance was found in 25.0% (4 of 16) and 12.5% (2 of 16) of the patients, respectively. When all of these parameters were combined, about 40% of the responders suffered from relapse of ischemic symptoms at 3 years after treatment ( Figure 3A ). There was no significant difference of the relapse rate between hemodialysis and nonhemodialysis patients or between ASO and TAO patients ( Figure 3A) . Likewise, the relapse rate did not differ among ASO patients on hemodialysis, nonhemodialysis ASO patients, and TAO patients ( Figure 3A ).
There were no significant differences of the survival rate and the MACE-free rate between responders and nonresponders ( Figure 2B and data not shown) . When patients younger than 70 years old in the 2 groups were compared, however, the survival rate tended to be higher in responders than in nonresponders until 3 years after treatment ( Figure  3B ). We performed myocardial perfusion SPECT imaging to estimate myocardial ischemia before and after treatment. The extent of myocardial ischemia showed a significant decrease after treatment that persisted for 6 months ( Figure 3C and data not shown). This improvement was significantly associated with the peak plasma level of vascular endothelial growth factor (rϭ0.76, PϽ0.05 at 8 weeks) after treatment, suggesting that injection of PB-MNC into ischemic limbs increased the production of vascular endothelial growth factor and thus induced neovascularization of ischemic myocardium.
Discussion
In this study, we analyzed the long-term outcome of therapeutic neovascularization with PB-MNC. Overall, improvement of ischemic symptoms was observed in 60% to 70% of the treated patients. The annual major amputation rate was Ͻ10%, and the mortality rate was 20% at 2 years and 30% at 3 years in our patients ( Figures 1G and 2A) . In other populations similar to our patients, it has been reported that clinical improvement was achieved in 25% to 50% by standard therapy, whereas 30% to 50% of patients required major amputation within a year after conventional treatment. 20 -23 The reported mortality rate for patients receiving standard treatment is Ϸ20% at 1 year and between 40% and 70% after 5 years. 20 -23 Because this study was preliminary and did not have a placebo control group, it was difficult to assess precisely the efficacy and safety of cell therapy only in this study. Nevertheless, our results taken together with previous reports suggest that the performance of therapeutic neovascularization with PB-MNC might be safe and effective for patients with critical limb ischemia.
The improvement of rest pain and walking distance was less marked in ASO patients on dialysis ( Figure 1D and 1E, Table 2, and supplemental Table II) . Moreover, 4 of 5 major amputations occurred in ASO patients on dialysis ( Figure  1G ). Although it could be explained by an actual detrimental effect in ASO patients, it is possible that this treatment had been less effective for such patients. The survival rate of ASO patients on dialysis was lower than that of either nonhemodialysis ASO patients or TAO patients (Figure 2A) , and most of the adverse events (death, major amputation, and cardiovascular events) occurred in the ASO group (mainly in patients on dialysis; Figures 1G and 2B) . Thus, we need to be more cautious when we consider this treatment for ASO patients on dialysis. The worse outcome in these patients could be attributable to functional abnormalities of vascular cells and progenitor cells, which are associated with age and various risk factors. 24 -26 For example, there is evidence of a decrease in the number and angiogenic activity of endothelial progenitor cells in patients with chronic renal failure, 27 and it was reported that such impairment was reversed by amelioration of uremia after renal replacement therapy. 28 In contrast, we found no significant difference in the number of progenitor cells between hemodialysis and nonhemodialysis patients (Table 3) or between responders and nonresponders (Table  5) . We found that the number of progenitor cells was much lower in nonresponders from the nonhemodialysis group than in responders of the same group (supplemental Table VII) , and similar findings were observed in the TAO group (supplemental Table V ). However, no such differences were observed between responders and nonresponders in the hemodialysis group or the ASO group (supplemental Tables IV and VI), suggesting that the function of progenitor cells was impaired in nonresponders from these groups rather than cell numbers being reduced.
TAO patients showed a better response to this therapy than ASO patients with or without hemodialysis (supplemental Table II ). None of the TAO patients died, and only 1 TAO patient underwent major amputation during the observation period, and few cardiovascular events occurred in this population ( Figures 1G, 2A , and 2B), suggesting that TAO patients may be well suited for cell therapy. The better response of the TAO population may also have been achieved because they were younger and had fewer risk factors than ASO patients with or without hemodialysis.
The survival rate was very similar to the MACE-free rate, suggesting that cardiovascular disease influenced survival. Although cardiovascular events were not a direct cause of death in about half of the patients, they had several cardiovascular diseases (including stroke, coronary artery disease, and heart failure) that could compromise their ability to fight infection and regulate the fluid balance. Such impairment may in turn increase the incidence of severe infections like sepsis and aspiration pneumonia, as well as fatal renal failure. It has been suggested that neovascularization might induce the development of atherosclerotic plaque and that increased vascularity of atheroma could lead to plaque rupture. 29 -31 Our previous study demonstrated that plasma levels of proangiogenic cytokines were increased after cell therapy, particularly in responders. 18 Therefore, we performed coronary angiogra- Data are shown as meanϮSD or n (%). OR indicates odds ratio; CRF, chronic renal failure; HD, hemodialysis; CAD, coronary artery disease; CVD, cerebrovascular disease; VEGF, vascular endothelial growth factor. *OR and 95% CI for OR.
phy and myocardial perfusion SPECT imaging in all of the patients both before and after treatment. There was no significant increase of cardiovascular events (including progression of coronary artery disease) in responders compared with nonresponders, suggesting that therapeutic neovascularization with PB-MNC did not promote atherogenesis. In fact, this therapy may have a beneficial rather than an adverse effect on coronary atherosclerosis because the area of myocardial ischemia estimated by SPECT imaging showed a significant decrease after treatment, and this improvement was associated with an increase in the plasma levels of proangiogenic factors. Moreover, survival tended to be better in responders younger than 70 years old. We previously demonstrated in a model of therapeutic neovascularization that implanted mononuclear cells could enhance muscle regeneration and increase the expression of various proangiogenic cytokines by regenerating myocytes, thus promoting vascularization and contributing to limb salvage. Taken together with our findings in animal studies, these clinical results suggest that this treatment increases the production of proangiogenic factors in ischemic limbs, thereby reducing myocardial ischemia as well as improving survival.
Limitations
This study was not placebo-controlled, and we did not analyze the data prospectively. The subjects were heterogeneous in terms of the underlying disease, age distribution, and coronary risk factors. Moreover, the survival rate of ASO patients was lower than that of TAO patients, although death was not directly related to limb ischemia. Therefore, it was difficult to assess precisely the efficacy of cell therapy in the present study. 
